Esophageal cancer
Conditions
Interventions
Experimental group:Anlotinib combined with Penpulimab
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. No gender limit, patients aged 18-75 years; 2. Primary esophageal squamous cell carcinoma confirmed by pathology (including histology or cytology); 3. Patients with clinical stage of cT1b-cT2N +M0 or cT2-cT4a, any N, M0, who have been judged feasible for radical resection of esophageal cancer and need neoadjuvant therapy before surgery; 4. Patients are not eligible for neoadjuvant chemoradiotherapy due to their physical conditions, mainly including: (1) Patients aged >=70 years who are not recommended for concurrent chemoradiotherapy; (2) PS > 1 score; (3) Patients with lung underlying diseases and other reasons not eligible for concurrent chemoradiotherapy; 5. ECOG (Eastern Oncology Consortium) score: 0-2; 6. Normal function of major organs.
Exclusion criteria
Exclusion criteria: 1. Previously received surgery, radiotherapy, chemotherapy, targeted or immunotherapy for esophageal squamous cell carcinoma; 2. Patients with distant organ metastasis; 3. Patients with esophageal squamous cell carcinoma with active bleeding within 2 months of the primary lesion; Patients with tumor invasion of bronchus or large blood vessels and bleeding tendency; 4. Accompanied by other immune diseases, or long-term use of immunosuppressive agents or hormones; 5. Complicated with tumors of other organs; 6. Patients are difficult to communicate, or difficult to follow up for a long time; 7. The doctor feels that other circumstances are not appropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathologic complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;1-year disease-free survival rates; | — |
Countries
China
Contacts
Public ContactDing Zhenyu
West China Hospital, Sichuan University
Outcome results
None listed